Jaguar Health, Inc. Files 10-K/A Amendment

TL;DR

<b>Jaguar Health, Inc. has filed an amendment to its annual report for the fiscal year ending December 31, 2023.</b>

AI Summary

Jaguar Health, Inc. (JAGX) filed a Amended Annual Report (10-K/A) with the SEC on April 17, 2024. Jaguar Health, Inc. filed a 10-K/A (Amendment No. 1) on April 17, 2024. The filing pertains to the fiscal year ended December 31, 2023. The company's principal executive offices are located at 200 Pine Street, Suite 400, San Francisco, California. Jaguar Health, Inc. is incorporated in Delaware. The company's common stock trades on The Nasdaq Capital Market under the symbol JAGX.

Why It Matters

For investors and stakeholders tracking Jaguar Health, Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year 2023, which is crucial for investors to have the most current data for analysis. The 10-K/A filing indicates potential revisions or additions to the original 10-K, which could impact the understanding of the company's financial health and operational status.

Risk Assessment

Risk Level: low — Jaguar Health, Inc. shows low risk based on this filing. The filing is an amendment (10-K/A) to a previous filing, suggesting that the original report may have contained inaccuracies or required updates, but the nature of these changes is not detailed in the provided header information.

Analyst Insight

Review the full amended 10-K filing to understand the specific changes made from the original 10-K and their potential impact on Jaguar Health's financial and operational standing.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the 10-K/A filing.)
• 2024-04-17 — Filing Date (The date the 10-K/A amendment was filed.)
• 001-36714 — Commission File Number (SEC file number for Jaguar Health, Inc.)
• 46-2956775 — IRS Employer Identification No. (Tax identification number for Jaguar Health, Inc.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant name
• JAGX (company) — Trading symbol
• 200 Pine Street, Suite 400 (location) — Business address
• San Francisco, California (location) — Business address city and state
• Delaware (location) — State of incorporation
• The Nasdaq Capital Market (company) — Exchange where common stock is registered
• 2023-12-31 (date) — Fiscal year end
• 2024-04-17 (date) — Filing date

FAQ

Industry Context

Jaguar Health, Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing products for specific medical conditions.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments (10-K/A).

What Investors Should Do

1. Obtain and review the full 10-K/A filing to identify all amendments and their implications.
2. Analyze the company's financial statements and management discussion for any changes or new disclosures.
3. Assess the impact of any revised information on Jaguar Health's stock performance and future outlook.

Key Dates

• 2023-12-31: Fiscal Year End — The period for which the annual report is filed.
• 2024-04-17: Filing Date — Date of the 10-K/A amendment submission.

Year-Over-Year Comparison

This is an amended filing (10-K/A), indicating that it supplements or corrects information previously provided in the original 10-K filing for the fiscal year ended December 31, 2023.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share JAGX The Nasdaq Capital Mar

Filing Documents

• tm2411648d3_10ka.htm (10-K/A) — 365KB
• tm2411648d3_ex31-1.htm (EX-31.1) — 4KB
• tm2411648d3_ex31-2.htm (EX-31.2) — 3KB
• tm2411648d3_img001.jpg (GRAPHIC) — 71KB
• tm2411648d3_img002.jpg (GRAPHIC) — 79KB
• 0001104659-24-048398.txt (&nbsp;) — 1057KB
• jagx-20231231.xsd (EX-101.SCH) — 3KB
• jagx-20231231_def.xml (EX-101.DEF) — 28KB
• jagx-20231231_lab.xml (EX-101.LAB) — 38KB
• jagx-20231231_pre.xml (EX-101.PRE) — 27KB
• tm2411648d3_10ka_htm.xml (XML) — 7KB

Executive Compensation

Executive Compensation 10 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 22 Item 13. Certain Relationships and Related Transactions, and Director Independence 25 Item 14. Principal Accounting Fees and Services 31 PART IV Item 15. Exhibits, Financial Statement Schedules 32 2 EXPLANATORY NOTE This Amendment No. 1 (this "Amendment") amends the Annual Report on Form 10–K for the year ended December 31, 2023 of Jaguar Health, Inc. (the "Company"), filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024 (the "Original Form 10–K"). The purpose of this Amendment is solely to amend Part III, Items 10 through 14 of the Original Form 10-K to include information previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K which permits the above-referenced Items to be incorporated in the Annual Report on Form 10-K by reference from a definitive proxy statement, if such proxy statement is filed no later than 120 days after December 31, 2023. At this time, the Company is filing this Amendment to include Part III information in our Annual Report on Form 10-K because we do not intend to file a definitive proxy statement within 120 days of December 31, 2023. Accordingly, Part III of the Original Form 10-K is hereby amended and restated as set forth herein. The information included herein as required by Part III, Items 10 through 14 of Form 10-K is more limited than what is required to be included in the definitive proxy statement to be filed in connection with our annual meeting of stockholders. Accordingly, the definitive proxy statement to be filed at a later date will include additional information related to the topics herein and additional information not required by Part III, Items 10 through 14 of Form 10-K. The reference on the cover page of the Original Form 10-K to the incorporation by reference of our definitive proxy statement into Part III of the Original Form 10-K i

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance The following table sets forth the name, age (as of April 17, 2024) and position of each of our executives and directors. Name Age Position(s) Held Executives Lisa Conte 65 Chief Executive Officer and President, Director (Class I) Pravin Chaturvedi, PhD 61 Chief Scientific Officer; Chair of Scientific Advisory Board Carol Lizak, MBA 60 Chief Financial Officer Steve King, PhD 66 Chief Sustainable Supply, Ethnobotanical Research, and IP Officer Jonathan Wolin, JD, MBA 62 Chief of Staff, Chief Compliance Officer, and General Counsel Non-Executive Directors James J. Bochnowski (1)(2)(3) 80 Chairman of the Board (Class I) John Micek III (1)(3) 71 Director (Class II) Jonathan B. Siegel (1)(2) 50 Director (Class I) Anula Jayasuriya 67 Director (Class III) (1) Member of the audit committee. (2) Member of the compensation committee. (3) Member of the nominating committee. Executive Team Lisa A. Conte. Ms. Conte has served as our President, Chief Executive Officer and a member of our board of directors since she founded the Company in June 2013. Ms. Conte also serves as the Chief Executive Officer and a member of the board of Napo since she founded Napo in November 2001 and is the Chairman of the board of our majority owned subsidiary Napo Therapeutics, S.p.A. (f/k/a Napo EU S.p.A.) ("Napo Therapeutics") since its inception in March 2021. In 1989, Ms. Conte founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company. Ms. Conte is also currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation, and serves on the Editorial Advisory Board of Life Science Leader magazine and on the Leadership Council of Pure Earth. Ms. Conte holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth Colle

View Full Filing

View this 10-K/A filing on SEC EDGAR